Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma
Status:
Terminated
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine if a short-term treatment with pazopanib, an oral
drug inhibiting the growth of blood vessel, can reduce the metabolism of soft-tissue sarcomas
and thus facilitate their resection when given prior to surgery. Moreover, the study assesses
the prognostic and predictive value of several new biomarkers (endothelial progenitor cells,
soluble vascular epithelial growth factor),
Phase:
Phase 2
Details
Lead Sponsor:
Heidelberg University
Collaborators:
German Cancer Research Center GlaxoSmithKline Klinikum Frankfurt Höchst Klinikum Frankfurt Hoechst Universitätsmedizin Mannheim University Hospital Heidelberg